Alzheimer's disease research is at a pivotal moment following recent FDA approvals of amyloid-targeting antibodies (lecanemab, donanemab), which have validated the amyloid hypothesis after decades of failures and opened the door to disease-modifying treatment in early symptomatic disease. Trials now focus on earlier intervention, combination approaches, and non-amyloid targets including tau, neuroinflammation, and synaptic loss.
Current trials investigate anti-tau antibodies, microglial activators, BACE inhibitors, GLP-1 agonists repurposed for neuroprotection, and lifestyle interventions for prevention in APOE4 carriers. Plasma biomarkers (p-tau217, Aβ42/40 ratio) are increasingly used for enrollment screening, replacing expensive PET scans.
Most disease-modifying trials require early-stage disease (mild cognitive impairment or mild dementia) with confirmed amyloid pathology by PET or CSF biomarkers.
Frequently Asked Questions — late onset alzheimer disease Clinical Trials
How many clinical trials are currently recruiting for late onset alzheimer disease?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for late onset alzheimer disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for late onset alzheimer disease?
late onset alzheimer disease research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a late onset alzheimer disease clinical trial?
Eligibility criteria for late onset alzheimer disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Indiana University 1 trial
Recruiting Clinical Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: April 2026 ·
Data Methodology